“换还是不换”：生物类似药文献拼图中缺失的一块？ - Suppr

Suppr

超能文献

'To switch or not to switch': the missing piece in the puzzle of biosimilar literature?

作者信息

Scherlinger Marc, Schaeverbeke Thierry

机构信息

Service de Rhumatologie, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France

Université de Bordeaux, Bordeaux, France.

出版信息

Ann Rheum Dis. 2020 Apr;79(4):e36. doi: 10.1136/annrheumdis-2018-214908. Epub 2019 Jan 4.

DOI:10.1136/annrheumdis-2018-214908

PMID:30610068

Abstract

摘要

相似文献

'To switch or not to switch': the missing piece in the puzzle of biosimilar literature?“换还是不换”：生物类似药文献拼图中缺失的一块？

Ann Rheum Dis. 2020 Apr;79(4):e36. doi: 10.1136/annrheumdis-2018-214908. Epub 2019 Jan 4.

Response to ''To switch or not to switch': the missing piece in the puzzle of biosimilar literature?' by Scherlinger .对舍林格所著《“转换还是不转换”：生物类似药文献谜题中缺失的一环？》的回应

Ann Rheum Dis. 2020 Apr;79(4):e37. doi: 10.1136/annrheumdis-2018-214952. Epub 2019 Jan 23.

Mandatory, cost-driven switching from originator etanercept to its biosimilar SB4: possible fallout on non-medical switching.强制的、成本驱动的从原研药依那西普转换为其生物类似药SB4：对非医学转换可能产生的影响。

Ann Rheum Dis. 2020 Feb;79(2):e13. doi: 10.1136/annrheumdis-2018-214757. Epub 2018 Nov 28.

To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry.是否切换：全国强制性从原研药切换至生物类似药依那西普的指南结果。DANBIO 登记处 2061 例炎性关节炎患者的 1 年治疗结果。

Ann Rheum Dis. 2019 Feb;78(2):192-200. doi: 10.1136/annrheumdis-2018-213474. Epub 2018 Nov 5.

Acceptance rate and sociological factors involved in the switch from originator to biosimilar etanercept (SB4).从原研药到生物类似药依那西普（SB4）转换过程中的接受率和社会学因素。

Semin Arthritis Rheum. 2019 Apr;48(5):927-932. doi: 10.1016/j.semarthrit.2018.07.005. Epub 2018 Jul 20.

Response to: 'Mandatory, cost-driven switching from originator etanercept to its biosimilar SB: possible fallout on non-medical switching' by Cantini and Benucci.对坎蒂尼和贝努奇所著《强制、成本驱动下从原研依那西普转换为其生物类似药SB：非医学转换可能产生的影响》的回应

Ann Rheum Dis. 2020 Feb;79(2):e14. doi: 10.1136/annrheumdis-2018-214788. Epub 2018 Dec 20.

Comparing the immunogenicity of the etanercept biosimilar SB4 with the innovator etanercept: another consideration.比较依那西普生物类似药SB4与原研依那西普的免疫原性：另一项考量

Ann Rheum Dis. 2016 Jul;75(7):e37. doi: 10.1136/annrheumdis-2016-209502. Epub 2016 Mar 31.

Post-switch Effectiveness of Etanercept Biosimilar Versus Continued Etanercept in Rheumatoid Arthritis Patients with Stable Disease: A Prospective Multinational Observational Study.依那西普生物类似药转换治疗与继续使用依那西普治疗对病情稳定的类风湿关节炎患者的疗效：一项前瞻性多国观察性研究。

Adv Ther. 2022 Nov;39(11):5259-5273. doi: 10.1007/s12325-022-02303-1. Epub 2022 Sep 22.

Etanercept originator versus etanercept biosimilar for the treatment of rheumatoid arthritis as a first biologic: results from the BSRBR-RA.依那西普原研药与依那西普生物类似药治疗类风湿关节炎作为一线生物制剂的比较：来自 BSRBR-RA 的结果。

Rheumatology (Oxford). 2023 Dec 1;62(12):3849-3857. doi: 10.1093/rheumatology/kead127.

Changes in etanercept and adalimumab biosimilar prescriptions for the initial treatment of rheumatoid arthritis in France: Data from the ART-SFR Registry.法国类风湿关节炎初始治疗中依那西普和阿达木单抗生物类似药处方的变化：来自ART-SFR注册研究的数据

Joint Bone Spine. 2022 May;89(3):105310. doi: 10.1016/j.jbspin.2021.105310. Epub 2021 Nov 25.

引用本文的文献

Advances in the treatment of systemic lupus erythematosus.系统性红斑狼疮治疗的进展

Nat Rev Drug Discov. 2025 Jul 17. doi: 10.1038/s41573-025-01242-0.

J Korean Med Sci. 2021 May 24;36(20):e143. doi: 10.3346/jkms.2021.36.e143.

Factors for starting biosimilar TNF inhibitors in patients with rheumatic diseases in the real world.真实世界中开始使用生物类似物 TNF 抑制剂治疗风湿性疾病患者的因素。

PLoS One. 2020 Jan 24;15(1):e0227960. doi: 10.1371/journal.pone.0227960. eCollection 2020.

Does a mandatory non-medical switch from originator to biosimilar etanercept lead to increase in healthcare use and costs? A Danish register-based study of patients with inflammatory arthritis.从原研药到生物类似药依那西普的强制性非医学转换是否会导致炎症性关节炎患者的医疗保健使用和成本增加？一项丹麦基于登记的研究。

RMD Open. 2019 Aug 12;5(2):e001016. doi: 10.1136/rmdopen-2019-001016. eCollection 2019.

RMD Open. 2019 May 21;5(1):e000900. doi: 10.1136/rmdopen-2019-000900. eCollection 2019.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验